New Rules On Medical Marijuana Research Could Play Into Pennsylvania Legislative Process

PENNSYLVANIA:  Last week the U.S. Drug Enforcement Administration relaxed regulations on medical marijuana research, with potential implications for approval of laws in Pennsylvania.

Loosening regulations on medical marijuana research should streamline the process for researchers conducting FDA-approved clinical trials on cannabidiol, or CBD, an extract of the marijuana plant, according to a news release from the DEA.

While good news for researchers, who have the potential to provide more information on its uses, the change in research protocols could affect the timetable for approving legislation to legalize medical marijuana for certain illnesses.

Pennsylvania’s medical marijuana bill was approved by the Senate last year and is currently being amended in the House.